Evidence map›Paper›PMID 42152691›Full record

ArticlePediatric dermatology

Dupilumab-Induced Psoriasis in an Adolescent With Severe Atopic Dermatitis: Successful Management With Abrocitinib.

Grigorios Theodosiou, Åke Svensson

Abstract readCase Reports
In one paragraph

Article in Pediatric dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Grigorios TheodosiouDepartment of Clinical Sciences, Lund University, Lund, Sweden.ORCID https://orcid.org/0000-0003-1656-7493
Åke SvenssonDepartment of Clinical Sciences, Lund University, Lund, Sweden.ORCID https://orcid.org/0000-0002-2821-7418

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasiform eruptions have been described in patients treated with dupilumab. This case report describes an adolescent with severe atopic dermatitis who developed a widespread psoriasiform dermatitis 8 months after starting dupilumab. His therapy was switched to abrocitinib resulting in near-complete resolution of the psoriatic lesions with good atopic dermatitis control. This case adds to the limited pediatric literature on dupilumab-induced psoriasis and highlights abrocitinib as an effective therapeutic alternative capable of addressing both conditions concurrently.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedDermatitis, AtopicPsoriasisPyrimidinesAdolescentDermatologic AgentsHumansMaleSeverity of Illness IndexTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDermatologic AgentsdupilumabPyrimidines

Identifiers

PMID42152691
PMCPMC13617169

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.